Merck & Co (MRK) DIvidends Date & History

Key Takeaways

• Merck & Co., Inc. (MRK) offers a current dividend yield of approximately 2.36% with an annualized payout of $3.40 per share.
• The company pays dividends quarterly and has raised its dividend for 14 consecutive years.
• Free cash flow coverage supports the dividend at around 52%, indicating solid sustainability despite varying earnings payout ratios.
• Dividend growth has averaged about 5% annually in recent periods, positioning MRK as a dividend growth stock.
• The payout profile appeals to long-term investors seeking moderate income with consistent increases.
• Compared to peers, MRK's yield is competitive within the large-cap pharmaceutical sector.

Dividend Overview

Merck & Co., Inc. (MRK) maintains a quarterly dividend policy with payments typically declared in advance and distributed in January, April, July, and October. The current annualized dividend stands at $3.40 per share, delivering a yield near 2.36% based on recent share prices. The most recent quarterly dividend of $0.85 per share has an ex-dividend date of September 15, 2026, and a payment date of October 7, 2026. MRK qualifies as a dividend growth stock rather than a high-yield name, emphasizing steady increases over time alongside its pharmaceutical operations focused on innovative medicines and vaccines.

Dividend History and Growth

Merck & Co., Inc. (MRK) has demonstrated consistent dividend growth, increasing its payout for 14 straight years. Annualized dividends have risen from $2.80 in earlier periods to the current $3.40 level, reflecting compounded annual growth rates of approximately 5% over the past three to five years. Recent quarterly hikes moved the payment from $0.81 to $0.85, aligning with the company's strategy of modest but reliable annual adjustments. This track record underscores a long-term commitment to returning capital to shareholders while funding research and development.

Dividend Sustainability and Payout Ratio

Dividend sustainability for Merck & Co., Inc. (MRK) appears supported by strong free cash flow generation, with the free cash flow payout ratio near 52%. Earnings-based payout ratios have fluctuated due to quarterly variations and one-time items, sometimes appearing elevated, yet normalized figures and analyst projections suggest adequate coverage. The company's robust balance sheet, diversified product portfolio including Keytruda, and consistent cash flows from operations provide a stable foundation for ongoing payments without undue strain on liquidity or debt levels.

Dividend Compared to Industry Peers

Within the large-cap pharmaceutical sector, Merck & Co., Inc. (MRK)'s yield of about 2.36% sits in line with or modestly below certain peers such as Johnson & Johnson while exceeding some others like Pfizer in recent comparisons. The 14-year growth streak and free cash flow coverage differentiate MRK favorably against companies with shorter histories or higher leverage. Overall, the profile reflects a balanced approach typical of established pharma firms prioritizing both innovation and shareholder returns.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking dividend opportunities like Merck & Co., Inc. (MRK) may find the platform useful for refining searches.

Is This Stock Attractive for Dividend Investors?

Merck & Co., Inc. (MRK) may suit dividend growth investors and long-term income seekers who value consistent annual increases and moderate yields over high immediate payouts. The 14-year streak and free cash flow support appeal to those prioritizing sustainability and gradual income growth. Conservative investors focused on established healthcare companies could find the profile attractive due to the company's scale and product pipeline. Income-oriented investors seeking higher yields might consider it supplementary rather than primary, while those emphasizing total return may appreciate the combination of dividends and potential capital appreciation from pharmaceutical innovation. The stock does not target high-yield seekers exclusively.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations